HCA Healthcare (NYSE:HCA) PT Raised to $230.00

HCA Healthcare (NYSE:HCAGet Rating) had its price target upped by Mizuho from $210.00 to $230.00 in a note issued to investors on Tuesday, The Fly reports. The brokerage presently has a “maintains” rating on the stock. Mizuho’s target price indicates a potential upside of 6.25% from the company’s previous close.

Several other analysts also recently weighed in on HCA. Cowen dropped their target price on shares of HCA Healthcare from $265.00 to $241.00 in a report on Monday, April 25th. SVB Leerink lifted their target price on shares of HCA Healthcare from $212.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, July 25th. Raymond James reiterated a “maintains” rating on shares of HCA Healthcare in a report on Tuesday, July 26th. Oppenheimer set a $255.00 price target on shares of HCA Healthcare in a research note on Monday, June 20th. Finally, Royal Bank of Canada dropped their price target on shares of HCA Healthcare from $256.00 to $249.00 and set a “maintains” rating for the company in a research note on Monday, July 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $236.59.

HCA Healthcare Trading Up 2.4 %

HCA opened at $216.47 on Tuesday. The company has a debt-to-equity ratio of 87.46, a current ratio of 1.55 and a quick ratio of 1.32. The company’s 50 day simple moving average is $188.67 and its two-hundred day simple moving average is $223.78. HCA Healthcare has a 1-year low of $164.47 and a 1-year high of $279.02. The firm has a market capitalization of $63.96 billion, a price-to-earnings ratio of 10.41, a price-to-earnings-growth ratio of 1.65 and a beta of 1.72.

HCA Healthcare (NYSE:HCAGet Rating) last released its quarterly earnings results on Friday, July 22nd. The company reported $4.21 EPS for the quarter, beating the consensus estimate of $3.67 by $0.54. The firm had revenue of $14.82 billion for the quarter, compared to analyst estimates of $14.73 billion. HCA Healthcare had a net margin of 10.83% and a return on equity of 833.68%. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.37 EPS. Analysts expect that HCA Healthcare will post 17.07 EPS for the current fiscal year.

Insider Activity

In other news, SVP Jennifer Berres sold 2,358 shares of the company’s stock in a transaction dated Friday, May 13th. The shares were sold at an average price of $218.87, for a total value of $516,095.46. Following the completion of the sale, the senior vice president now directly owns 11,392 shares of the company’s stock, valued at $2,493,367.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Patricia F. Elcan purchased 325 shares of the company’s stock in a transaction dated Monday, July 25th. The shares were acquired at an average cost of $198.66 per share, for a total transaction of $64,564.50. Following the completion of the purchase, the insider now directly owns 89,337 shares in the company, valued at approximately $17,747,688.42. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jennifer Berres sold 2,358 shares of the business’s stock in a transaction dated Friday, May 13th. The stock was sold at an average price of $218.87, for a total transaction of $516,095.46. Following the transaction, the senior vice president now owns 11,392 shares in the company, valued at $2,493,367.04. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baltimore Washington Financial Advisors Inc. acquired a new stake in shares of HCA Healthcare in the fourth quarter valued at approximately $26,000. GoalVest Advisory LLC acquired a new stake in shares of HCA Healthcare in the first quarter valued at approximately $26,000. Wolff Wiese Magana LLC grew its position in shares of HCA Healthcare by 1,833.3% in the first quarter. Wolff Wiese Magana LLC now owns 116 shares of the company’s stock valued at $29,000 after purchasing an additional 110 shares during the last quarter. J.W. Cole Advisors Inc. purchased a new position in shares of HCA Healthcare during the first quarter valued at approximately $29,000. Finally, PYA Waltman Capital LLC purchased a new position in shares of HCA Healthcare during the fourth quarter valued at approximately $31,000. 67.87% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Company Profile

(Get Rating)

HCA Healthcare, Inc, through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Recommended Stories

The Fly logo

Analyst Recommendations for HCA Healthcare (NYSE:HCA)

Want More Great Investing Ideas?

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.